The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
Open accessAbstract
A hyperinflammatory syndrome (HIS) may cause a life-threatening acute respiratory distress syndrome (ARDS) in patients with COVID-19 pneumonia. A prospective series of 100 consecutive patients admitted to the Spedali Civili University Hospital in Brescia (Italy) between March 9th and March 20th with confirmed COVID-19 pneumonia and ARDS requiring ventilatory support was analyzed to determine whether intravenous administration of tocilizumab (TCZ), a monoclonal antibody that targets the interleukin 6 (IL-6) receptor, was associated with improved outcome. Tocilizumab was administered at a dosage of 8 mg/kg by two consecutive intravenous infusions 12 h apart. A third infusion was optional based on clinical response. The outcome measure was an improvement in acute respiratory failure assessed by means of the Brescia COVID Respiratory Severity Score (BCRSS 0 to 8, with higher scores indicating higher severity) at 24–72 h and 10 days after tocilizumab administration. Out of 100 treated patients (88 M, 12 F; median age: 62 years), 43 received TCZ in the intensive care unit (ICU), while 57 in the general ward as no ICU beds were available. Of these 57 patients, 37 (65%) improved and suspended noninvasive ventilation (NIV) (median BCRSS: 1 [IQR 0–2]), 7 (12%) patients remained stable in NIV, and 13 (23%) patients worsened (10 died, 3 were admitted to ICU). Of the 43 patients treated in the ICU, 32 (74%) improved (17 of them were taken off the ventilator and were discharged to the ward), 1 (2%) remained stable (BCRSS: 5) and 10 (24%) died (all of them had BCRSS≥7 before TCZ). Overall at 10 days, the respiratory condition was improved or stabilized in 77 (77%) patients, of whom 61 showed a significant clearing of diffuse bilateral opacities on chest x-ray and 15 were discharged from the hospital. Respiratory condition worsened in 23 (23%) patients, of whom 20 (20%) died. All the patients presented with lymphopenia and high levels of C-reactive protein (CRP), fibrinogen, ferritin and IL-6 indicating a HIS. During the 10-day follow-up, three cases of severe adverse events were recorded: two patients developed septic shock and died, one had gastrointestinal perforation requiring urgent surgery and was alive at day 10. In conclusion, our series showed that COVID-19 pneumonia with ARDS was characterized by HIS. The response to TCZ was rapid, sustained, and associated with significant clinical improvement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., et al. (2020) · JAMA · doi:10.1001/jama.2020.5394 · Cited by 5,469 · cited 1×
“After the first epidemic of Coronavirus associated disease (COVID19) sustained by SARS-CoV-2 in Wuhan (China), the region of Lombardy in Northern Italy has become the second most affected area in the world [1,2].”
Self-citationEffective treatment of severe COVID-19 patients with tocilizumab
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,647
Grasselli, G., Pesenti, A., & Cecconi, M. (2020) · JAMA · doi:10.1001/jama.2020.4031 · Cited by 2,023
McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102537 · Cited by 1,654
Adult haemophagocytic syndrome
Ramos-Casals, M., Brito-Zerón, P., López-Guillermo, A., Khamashta, M. A., & Bosch, X. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61048-x · Cited by 1,442
Villar, J., Ferrando, C., Martínez, D., Ambrós, A., Muñoz, T., Soler, J. A., Aguilar, G., Alba, F., González-Higueras, E., Conesa, L. A., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30417-5 · Cited by 1,199
Laboratory abnormalities in patients with COVID-2019 infection
Lippi, G., & Plebani, M. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-0198 · Cited by 1,020
Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., & Kakehi, T. (2008) · Blood · doi:10.1182/blood-2008-05-155846 · Cited by 795
The Toughest Triage — Allocating Ventilators in a Pandemic
Truog, R. D., Mitchell, C., & Daley, G. Q. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005689 · Cited by 700
Wan, S., Yi, Q., Fan, S., Lv, J., Zhang, X., Guo, L., Lang, C., Xiao, Q., Xiao, K., Yi, Z., et al. (2020) · doi:10.1101/2020.02.10.20021832 · Cited by 562
Rosário, C., Zandman-Goddard, G., Meyron-Holtz, E. G., D’Cruz, D. P., & Shoenfeld, Y. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-185 · Cited by 466
Lau, S. K. P., Lau, C. C. Y., Chan, K.-H., Li, C. P. Y., Chen, H., Jin, D.-Y., Chan, J. F. W., Woo, P. C. Y., & Yuen, K.-Y. (2013) · Journal of General Virology · doi:10.1099/vir.0.055533-0 · Cited by 392
Caso, F., Costa, L., Ruscitti, P., Navarini, L., PUENTE, A. D., Giacomelli, R., & Scarpa, R. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102524 · Cited by 317
Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis
Karakike, E., & Giamarellos-Bourboulis, E. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00055 · Cited by 304
Shoenfeld, Y. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102538 · Cited by 227
Piva, S., Filippini, M., Turla, F., Cattaneo, S., Margola, A., De Fulviis, S., Nardiello, I., Beretta, A., Ferrari, L., Trotta, R., et al. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.04.004 · Cited by 171
Self-citationFindings of Acute Pulmonary Embolism in COVID-19 PatientsPreprint
Chen, J., Wang, X., Zhang, S., Liu, B., Wu, X., Wang, Y., Wang, X., Yang, M. J., Sun, J., & Xie, Y. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3548771 · Cited by 107
Ruscitti, P., Berardicurti, O., Benedetto, P. D., Cipriani, P., Iagnocco, A., Shoenfeld, Y., & Giacomelli, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01130 · Cited by 104
Clinical research in critically ill patients: the situation in Italy
Zamperetti, N., & Latronico, N. (2008) · Intensive Care Medicine · doi:10.1007/s00134-008-1096-6 · Cited by 16
Self-citationAlahmari, A. D. (2015) · Journal of Applied Hematology · doi:10.4103/1658-5127.155168 · Cited by 8
Cited by
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
Stone, J. H., Frigault, M. J., Serling-Boyd, N. J., Fernandes, A. D., Harvey, L., Foulkes, A. S., Horick, N. K., Healy, B. C., Shah, R., Bensaci, A. M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028836 · Cited by 1,362
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
Guaraldi, G., Meschiari, M., Cozzi-Lepri, A., Milic, J., Tonelli, R., Menozzi, M., Franceschini, E., Cuomo, G., Orlando, G., Borghi, V., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30173-9 · Cited by 939
Salvarani, C., Dolci, G., Massari, M., Merlo, D. F., Cavuto, S., Savoldi, L., Bruzzi, P., Boni, F., Braglia, L., Turrà, C., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6615 · Cited by 684
How COVID-19 induces cytokine storm with high mortality
Hojyo, S., Uchida, M., Tanaka, K., Hasebe, R., Tanaka, Y., Murakami, M., & Hirano, T. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00146-3 · Cited by 663
“100 rapidly improved clinical and respiratory status after TCZ treatment [73].”
BackgroundCOVID-19 infection: an overview on cytokine storm and related interventions
Montazersaheb, S., Hosseiniyan Khatibi, S. M., Hejazi, M. S., Tarhriz, V., Farjami, A., Ghasemian Sorbeni, F., Farahzadi, R., & Ghasemnejad, T. (2022) · Virology Journal · doi:10.1186/s12985-022-01814-1 · Cited by 610
Metadata
- Authors
- Toniati, P., Piva, S., Cattalini, M., Garrafa, E., Regola, F., Castelli, F., Franceschini, F., Airò, P., Bazzani, C., Beindorf, E.-A., Berlendis, M., Bezzi, M., Bossini, N., Castellano, M., Cattaneo, S., Cavazzana, I., Contessi, G.-B., Crippa, M., Delbarba, A., De Peri, E., Faletti, A., Filippini, M., Filippini, M., Frassi, M., Gaggiotti, M., Gorla, R., Lanspa, M., Lorenzotti, S., Marino, R., Maroldi, R., Metra, M., Matteelli, A., Modina, D., Moioli, G., Montani, G., Muiesan, M.-L., Odolini, S., Peli, E., Pesenti, S., Pezzoli, M.-C., Pirola, I., Pozzi, A., Proto, A., Rasulo, F.-A., Renisi, G., Ricci, C., Rizzoni, D., Romanelli, G., Rossi, M., Salvetti, M., Scolari, F., Signorini, L., Taglietti, M., Tomasoni, G., Tomasoni, L.-R., Turla, F., Valsecchi, A., Zani, D., Zuccalà, F., Zunica, F., Focà, E., Andreoli, L., & Latronico, N.
- Venue
- Autoimmunity Reviews
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 19
- Issue
- 7
- Pages
- 102568
- ISSN
- 1568-9972 (ISSN-L)
- OpenAlex
- W3021915688
- Cited by
- 751
- References
- 22
- FWCI
- 21.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.